Yifeng Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yifeng Zhou has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Jiachun Lu
School of public health, Guangzhou medical university, Guangzhou, China
72 shared publications - Binbin Guo
Department of Genetics, School of Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, China
67 shared publications - Shenghua Zhang
Jiangsu Clinical Medicine Research Institute, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
67 shared publications - Jian Zheng
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China
66 shared publications - Fanrong Li
Department of Genetics, Medical College of Soochow University, Suzhou, Jiangsu, China
65 shared publications - Jieqiong Deng
Department of Genetics, Medical College of Soochow University, Suzhou, Jiangsu, China
65 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
The long non-coding RNA UGDH-AS1 encodes an NK-cell-inhibiting micropeptide in triple-negative breast cancers
NK cells are important for the anti-tumour immune response for their potential to kill MHC class I-deficient tumor cells, but they often become dysfunctional in the immune-hostile tumour microenvironment. Here, using single-cell RNA sequencing, we identify an NK cell subpopulation that is specific to triple-negative breast cancers (TNBC) subtype, characterised by the expression of the long non-coding RNA UGDH-AS1. In these NK cells, UGDH-AS1 encodes the micropeptide, NKSM, which renders these NK cells dysfunctional due to the loss of their activation program, which leads to cancer progression. Conditional NKSM knock-in into NK cells of mice results in NK cell deactivation and increased growth of transplanted tumours. Targeted NKSM therapy effectively reduces tumor growth in TNBC mouse models. We find that UGDH-AS1+ NK cells are shaped by the tumor microenvironment (TME). Following upregulation by the TGF-β signaling pathway, NKSM binds to Myc, inhibiting its ERK1/2-mediated phosphorylation at Serine 62 and thus reducing its stability. Decreased Myc activity results in deregulation of T-bet, a key protein involved in NK cell function, which leads to NK cell deactivation. Our study thus provides mechanistic insight int NK cell dysfunctionality in TNBC and lays down the proof of principle for an NK-cell-targeting TNBC immunotherapy.
- 12 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessThe long non-coding RNA UGDH-AS1 encodes an NK-cell-inhibiting micropeptide in triple-negative breast cancers
NK cells are important for the anti-tumour immune response for their potential to kill MHC class I-deficient tumor cells, but they often become dysfunctional in the immune-hostile tumour microenvironment. Here, using single-cell RNA sequencing, we identify an NK cell subpopulation that is specific to triple-negative breast cancers (TNBC) subtype, characterised by the expression of the long non-coding RNA UGDH-AS1. In these NK cells, UGDH-AS1 encodes the micropeptide, NKSM, which renders these NK cells dysfunctional due to the loss of their activation program, which leads to cancer progression. Conditional NKSM knock-in into NK cells of mice results in NK cell deactivation and increased growth of transplanted tumours. Targeted NKSM therapy effectively reduces tumor growth in TNBC mouse models. We find that UGDH-AS1+ NK cells are shaped by the tumor microenvironment (TME). Following upregulation by the TGF-β signaling pathway, NKSM binds to Myc, inhibiting its ERK1/2-mediated phosphorylation at Serine 62 and thus reducing its stability. Decreased Myc activity results in deregulation of T-bet, a key protein involved in NK cell function, which leads to NK cell deactivation. Our study thus provides mechanistic insight int NK cell dysfunctionality in TNBC and lays down the proof of principle for an NK-cell-targeting TNBC immunotherapy.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Related information to figure 2, figure 3, and figure 5
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Related information to figure 2, figure 3, and figure 5
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Primary clinical and histological characteristics of 67 study patients
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Primary clinical and histological characteristics of 67 study patients
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
The genomic position of the predicted ORFs of the six lncRNAs
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
The genomic position of the predicted ORFs of the six lncRNAs
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Sequences of LINC00887 and ACLY-BP cDNA
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Sequences of LINC00887 and ACLY-BP cDNA
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Supplementary Materials and Methods
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Supplementary Materials and Methods
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Sequences of shRNAs and siRNAs used in this study
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Sequences of shRNAs and siRNAs used in this study
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Related information to figure 6
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Related information to figure 6